XML 38 R20.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Stockholders' Equity | 12 Months Ended
--- | ---
Apr. 26, 2024
Share-Based Payment Arrangement [Abstract] |
Stockholders' Equity | 10. Stockholders’ Equity Equity Incentive Programs The 2021 Plan — The 2021 Equity Incentive Plan (the 2021 Plan) was adopted by our Board of Directors and approved by the stockholders on September 10, 2021. The 2021 Plan replaced the 1999 Stock Option Plan (the 1999 Plan), and the 1999 Plan terminated effective as of September 11, 2021, except that the 1999 Plan will continue to govern awards outstanding thereunder as of the date of such plan’s termination and such awards will continue in force and effect until terminated pursuant to their terms. The 2021 Plan provides for the granting of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards to our employees, directors, and consultants. Under the 2021 Plan, the Board of Directors may grant to employees, nonemployee directors, consultants and independent advisors options to purchase shares of our common stock during their period of service. The exercise price for an incentive stock option and a nonstatutory option cannot be less than 100% of the fair market value of the common stock on the grant date. The 2021 Plan prohibits the repricing of any outstanding stock option or stock appreciation right after it has been granted or to cancel any outstanding stock option or stock appreciation right and immediately replace it with a new stock option or stock appreciation right with a lower exercise price unless approved by stockholders. RSUs granted under the 2021 Plan include time-based RSUs that generally vest over a four-year period with 25% vesting on the first anniversary of the grant date and 6.25% vesting quarterly thereafter. The Compensation Committee of the Board of Directors (the Compensation Committee) has the discretion to use different vesting schedules. In addition, performance-based RSUs may be granted under the 2021 Plan and are subject to performance criteria and vesting terms specified by the Compensation Committee. During fiscal 2024, the shares reserved for issuance under the Plan were increased by 13 million shares of common stock. As of April 26, 2024, 10 million shares were available for grant under the 2021 Plan. Stock Options Less than 1 million stock options were outstanding as of April 26, 2024 and April 28, 2023. Additional information related to our stock options is summarized below (in millions):
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
Intrinsic value of exercises |  | $ | 9 |  |  | $ | 7 |  |  | $ | 14 |
Proceeds received from exercises |  | $ | 2 |  |  | $ | 1 |  |  | $ | 1 |
Fair value of options vested |  | $ | 2 |  |  | $ | 4 |  |  | $ | 5 |
Restricted Stock Units In the first quarter of fiscal 2024, due to an insufficient number of remaining shares available for issuance under the 2021 Plan, most of the awards granted in that period were subject to cash settlement upon vesting, and accounted for as liability awards. However, in the second quarter of fiscal 2024, stockholders approved an increase in the number of shares available for issuance under the 2021 Plan, and these awards, by their terms, automatically became share-settled, equity-classified awards. The modification resulted in the elimination of the $4 million liability related to these awards, with a corresponding increase to additional paid-in capital, as presented on the Statements of Stockholders' Equity for the twelve months ended April 26, 2024. In fiscal 2024, 2023 and 2022, we granted PBRSUs to certain of our executives. Each PBRSU has performance-based vesting criteria (in addition to the service-based vesting criteria) such that the PBRSUs cliff-vest at the end of a three year performance period, which began on the date specified in the grant agreements and typically ends on the last day of the third fiscal year, following the grant date. The number of shares that will be used to calculate the settlement amount for all of these PBRSUs at the end of the applicable performance and service period will range from 0% to 200% of a target number of shares originally granted. For half of the PBRSUs granted in fiscal 2024 and 2023, and for most of the PBRSUs granted in fiscal 2022, the number of shares used to calculate the settlement amount will depend upon our Total Stockholder Return (TSR) as compared to the TSR of a specified group of benchmark peer companies (each expressed as a growth rate percentage) calculated as of the end of the performance period. For the remaining half of the PBRSUs granted in the fiscal 2024 and 2023, the number of shares used to calculate the settlement amount will depend upon the Company's billings result average over the three-year performance period. The billings result average is computed based on achievement against annual billings targets, with each target set at the beginning of the respective fiscal year, during the three-year performance period. Billings for purposes of measuring the performance of these PBRSUs means the total obtained by adding net revenues as reported on the Company's Consolidated Statements of Income to the amount reported as the change in deferred revenue and financed unearned services revenue on the Consolidated Statements of Cash Flows for the applicable measurement period, excluding the impact of fluctuations in foreign currency exchange rates. The aggregate grant date fair value of all PBRSUs granted in fiscal 2024, 2023 and 2022 was $39 million, $28 million and $59 million, respectively, and these amounts are being recognized to compensation expense over the remaining performance/service periods. As of April 26, 2024, April 28, 2023 and April 29, 2022, there were approximately 1 million PBRSUs outstanding. The following table summarizes information related to RSUs, including PBRSUs (in millions, except for fair value):
|  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value |
Outstanding as of April 30, 2021 |  |  | 9 |  |  | $ | 47.75 |
Granted |  |  | 5 |  |  | $ | 80.40 |
Vested |  |  | (3 | ) |  | $ | 48.91 |
Forfeited |  |  | (1 | ) |  | $ | 57.46 |
Outstanding as of April 29, 2022 |  |  | 10 |  |  | $ | 64.09 |
Granted |  |  | 8 |  |  | $ | 59.87 |
Vested |  |  | (4 | ) |  | $ | 62.85 |
Forfeited |  |  | (2 | ) |  | $ | 61.99 |
Outstanding as of April 28, 2023 |  |  | 12 |  |  | $ | 62.08 |
Granted |  |  | 5 |  |  | $ | 76.46 |
Vested |  |  | (5 | ) |  | $ | 59.32 |
Forfeited |  |  | (1 | ) |  | $ | 65.17 |
Outstanding as of April 26, 2024 |  |  | 11 |  |  | $ | 68.87 |
We primarily use the net share settlement approach upon vesting, where a portion of the shares are withheld as settlement of employee withholding taxes, which decreases the shares issued to the employee by a corresponding value. The number and value of the shares netted for employee taxes are summarized in the table below (in millions):
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
Shares withheld for taxes |  |  | 2 |  |  |  | 1 |  |  |  | 1 |
Fair value of shares withheld |  | $ | 128 |  |  | $ | 84 |  |  | $ | 74 |
Employee Stock Purchase Plan Eligible employees are offered shares through a 24-month offering period, which consists of four consecutive 6-month purchase periods. Employees may purchase a limited number of shares of the Company’s stock at a discount of up to 15% of the lesser of the market value at the beginning of the offering period or the end of each 6-month purchase period. On September 13, 2023, the ESPP was amended to increase the shares reserved for issuance by 3 million shares of common stock. As of April 26, 2024, 4 million shares were available for issuance. The following table summarizes activity related to the purchase rights issued under the ESPP (in millions):
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
Shares issued under the ESPP |  |  | 2 |  |  |  | 2 |  |  |  | 3 |
Proceeds from issuance of shares |  | $ | 99 |  |  | $ | 107 |  |  | $ | 104 |
Stock-Based Compensation Expense Stock-based compensation expense is included in the consolidated statements of income as follows (in millions):
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
Cost of product revenues |  | $ | 6 |  |  | $ | 5 |  |  | $ | 4 |
Cost of hardware support and other services revenues |  |  | 23 |  |  |  | 19 |  |  |  | 13 |
Sales and marketing |  |  | 143 |  |  |  | 135 |  |  |  | 115 |
Research and development |  |  | 132 |  |  |  | 111 |  |  |  | 75 |
General and administrative |  |  | 53 |  |  |  | 42 |  |  |  | 38 |
Total stock-based compensation expense |  | $ | 357 |  |  | $ | 312 |  |  | $ | 245 |
As of April 26, 2024, total unrecognized compensation expense related to our equity awards was $578 million, which is expected to be recognized on a straight-line basis over a weighted-average remaining service period of 2.0 years. Valuation Assumptions The valuation of RSUs and ESPP purchase rights and the underlying weighted-average assumptions are summarized as follows:
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
RSUs: |  |  |  |  |  |  |  |  |
Risk-free interest rate |  |  | 4.9 | % |  |  | 3.1 | % |  |  | 0.5 | %
Expected dividend yield |  |  | 2.6 | % |  |  | 2.9 | % |  |  | 2.4 | %
Weighted-average fair value per share granted |  | $ | 76.46 |  |  | $ | 59.87 |  |  | $ | 80.40 |
ESPP: |  |  |  |  |  |  |  |  |
Expected term in years |  |  | 1.2 |  |  |  | 1.2 |  |  |  | 1.2 |
Risk-free interest rate |  |  | 4.9 | % |  |  | 3.9 | % |  |  | 0.2 | %
Expected volatility |  |  | 30 | % |  |  | 36 | % |  |  | 37 | %
Expected dividend yield |  |  | 2.8 | % |  |  | 2.9 | % |  |  | 2.4 | %
Weighted-average fair value per right granted |  | $ | 17.37 |  |  | $ | 21.28 |  |  | $ | 24.75 |
Stock Repurchase Program As of April 26, 2024, our Board of Directors has authorized the repurchase of up to $16.1 billion of our common stock. Under this program, which we may suspend or discontinue at any time, we may purchase shares of our outstanding common stock through solicited or unsolicited transactions in the open market, in privately negotiated transactions, through accelerated share repurchase programs, pursuant to a Rule 10b5-1 plan or in such other manner as deemed appropriate by our management. The stock repurchase program may be suspended or discontinued at any time. The following table summarizes activity related to the stock repurchase program for our fiscal years of 2024, 2023 and 2022 (in millions, except for per share amounts):
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
Number of shares repurchased |  |  | 12 |  |  |  | 13 |  |  |  | 7 |
Average price per share |  | $ | 77.87 |  |  | $ | 66.42 |  |  | $ | 84.49 |
Stock repurchases allocated to additional paid-in capital |  | $ | 102 |  |  | $ | 45 |  |  | $ | 20 |
Stock repurchases allocated to retained earnings |  | $ | 798 |  |  | $ | 805 |  |  | $ | 580 |
Remaining authorization at end of period |  | $ | 502 |  |  | $ | 402 |  |  | $ | 1,252 |
Since the May 13, 2003 inception of our stock repurchase program through April 26, 2024, we repurchased a total of 372 million shares of our common stock at an average price of $42.04 per share, for an aggregate purchase price of $15.6 billion. On May 23, 2024 our Board of Directors authorized the repurchase of an additional $1.0 billion of our common stock. Preferred Stock Our Board of Directors has the authority to issue up to 5 million shares of preferred stock and to determine the price, rights, preferences, privileges, and restrictions, including voting rights, of those shares without any further vote or action by the stockholders. No shares of preferred stock were issued or outstanding in any period presented. Dividends The following is a summary of our fiscal 2024, 2023 and 2022 activities related to dividends on our common stock (in millions, except per share amounts).
|  | Year Ended |
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |
Dividends per share declared |  | $ | 2.00 |  |  | $ | 2.00 |  |  | $ | 2.00 |
Dividend payments allocated to additional paid-in capital |  | $ | 171 |  |  | $ | 106 |  |  | $ | — |
Dividend payments allocated to retained earnings |  | $ | 245 |  |  | $ | 326 |  |  | $ | 446 |
On May 23, 2024, we declared a cash dividend of $0.52 per share of common stock, payable on July 24, 2024 to shareholders of record as of the close of business on July 5, 2024. The timing and amount of future dividends will depend on market conditions, corporate business and financial considerations and regulatory requirements. All dividends declared have been determined by the Company to be legally authorized under the laws of the state in which we are incorporated. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) (AOCI) by component, net of tax, are summarized below (in millions):
|  | Foreign Currency Translation Adjustments |  |  | Defined Benefit Obligation Adjustments |  |  | Unrealized Gains (Losses) on Available- for-Sale Securities |  |  | Unrealized Gains (Losses) on Cash Flow Hedges |  |  | Total |
Balance as of April 30, 2021 |  | $ | (27 | ) |  | $ | (4 | ) |  | $ | 1 |  |  | $ | — |  |  | $ | (30 | )
OCI before reclassifications, net of tax |  |  | (17 | ) |  |  | 3 |  |  |  | (1 | ) |  |  | 8 |  |  |  | (7 | )
Amounts reclassified from AOCI, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (7 | ) |  |  | (7 | )
Total OCI |  |  | (17 | ) |  |  | 3 |  |  |  | (1 | ) |  |  | 1 |  |  |  | (14 | )
Balance as of April 29, 2022 |  |  | (44 | ) |  |  | (1 | ) |  |  | — |  |  |  | 1 |  |  |  | (44 | )
OCI before reclassifications, net of tax |  |  | (4 | ) |  |  | (2 | ) |  |  | — |  |  |  | (6 | ) |  |  | (12 | )
Amounts reclassified from AOCI, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5 |  |  |  | 5 |
Total OCI |  |  | (4 | ) |  |  | (2 | ) |  |  | — |  |  |  | (1 | ) |  |  | (7 | )
Balance as of April 28, 2023 |  |  | (48 | ) |  |  | (3 | ) |  |  | — |  |  |  | — |  |  |  | (51 | )
OCI before reclassifications, net of tax |  |  | (5 | ) |  |  | (4 | ) |  |  | — |  |  |  | 2 |  |  |  | (7 | )
Amounts reclassified from AOCI, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1 | ) |  |  | (1 | )
Total OCI |  |  | (5 | ) |  |  | (4 | ) |  |  | — |  |  |  | 1 |  |  |  | (8 | )
Balance as of April 26, 2024 |  | $ | (53 | ) |  | $ | (7 | ) |  | $ | — |  |  | $ | 1 |  |  | $ | (59 | )
The amounts reclassified out of AOCI are as follows (in millions):
|  | Year Ended |  |  | Statements of Income
|  | April 26, 2024 |  |  | April 28, 2023 |  |  | April 29, 2022 |  |  | Classification
Realized (gains) losses on cash flow hedges |  | $ | (1 | ) |  | $ | 5 |  |  | $ | (7 | ) |  | Net revenues
Total reclassifications |  | $ | (1 | ) |  | $ | 5 |  |  | $ | (7 | ) |  |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration